Novartis Signs Deal Worth up to $3.2 Billion for Alteogen’s Drug Delivery Technology
The agreement gives Novartis exclusive options to use Alteogen’s enzyme platform for injectable drugs, with payments tied to milestones, sales and royalties.
- On Wednesday, South Korea's Alteogen Inc. signed an option and licensing agreement with Novartis worth up to $3.22 billion, granting the Swiss drugmaker access to its ALT-B4 technology for developing injectable versions of intravenous drugs.
- Built on Alteogen's Hybrozyme platform, ALT-B4 enables biologic drugs traditionally administered intravenously to be converted into subcutaneous formulations by temporarily breaking down hyaluronan for faster absorption.
- The agreement includes option exercise fees, milestone payments, and royalties on future product sales, with Alteogen eligible to receive the full $3.22 billion if all development and commercial milestones are achieved.
- This Novartis deal marks Alteogen's fourth ALT-B4 licensing agreement this year, reflecting a broader industry trend where drugmakers increasingly develop under-the-skin versions of medicines to replace traditional intravenous infusions.
- Merck's Keytruda Qlex, which utilizes ALT-B4, received FDA approval last year, providing commercial validation that the technology effectively converts intravenous biologics into subcutaneous injections.
12 Articles
12 Articles
This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One
Novartis just committed billions not to discover a new drug but to change how an existing one enters your body. The reason why that quiet engineering bet could matter more than a blockbuster pipeline win is buried in the fine print.
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
South Korea's Alteogen said on Wednesday it has signed a deal with Novartis worth up to $3.22 billion, giving the Swiss drugmaker access to its technology to make injectable versions of intravenous drugs.
Alteogen announced on the 2nd that it has signed a technology transfer agreement with Novartis of Switzerland for the development and commercialization of ‘ALT-B4,’ based on the ‘Hybrozyme®’ platform technology that converts intravenous (IV) formulations of biopharmaceuticals into subcutaneous (SC) formulations. Under this agreement, Novartis holds exclusive rights to develop and commercialize multiple biopharmaceuticals in subcutaneous formulat…
(Seoul=Yonhap News) Reporter Shin Seon-mi = Alteogen [196170] is developing and commercializing ALT-B4 based subcutaneous injection (SC) pharmaceutical products with global pharmaceutical company Novartis...
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
